OBX

Conviction 0HealthcareScan · Thu, Oct 1, 2026

Obsidian Therapeutics, Inc. (OBX) closed at $13.32 (-2.99%) on Oct 1, 2026. RSI(14) 32, -61.9% from its 52-week high, -60.8% year to date. Sector: Healthcare · Biotechnology.

OBX$13.32-2.99%

ResistanceSupportVol 14

Vol MA14 895.78K

Aug 4Aug 14Aug 26Sep 9Sep 21Oct 1

Obsidian Therapeutics, Inc.Biotechnology

Price13.32

Change-2.99%

Gap+2.69%

Rel volume0.39×

Avg volume729.79K

Avg $ vol12.19M

SMA 2016.23

SMA 50—

SMA 200—

Price vs 50—

Price vs 200—

MA stack—

50/200 cross—

Supertrenddown · 19.00

RSI (14)32

MACD hist0.01

MACD crossbull · 1d

Stoch %K / %D17 / 24

ADX (14)23

+DI / −DI14 / 24

RSI divergence—

MACD divergence—

ATR %17.69%

ADR %10.61%

52w high35.00

52w low12.86

From 52w high-61.94%

Above 52w low+3.58%

New 52w highNo

SqueezeOn · 17d

Bollinger width47.15%

%B0.12

Donchian pos14.86%

Donchian high19.97

Donchian low12.16

AVWAP (52w high)17.44

vs AVWAP high-23.64%

AVWAP (52w low)13.44

vs AVWAP low-0.86%

OBV trendUp

Chaikin MF (20)-0.30

Today vs 20d0.39×

Avg vol (14d)895.78K

Avg vol (20d)729.79K

Avg $ vol (20d)12.19M

Market cap822.81M

RS Rating—

RS 3m (vs SPY)—

RS 6m (vs SPY)—

RS line new highNo

Trend template—

Technical rank19.4

1 week-0.67%

1 month-21.83%

3 months—

6 months—

1 year—

YTD-60.82%

P/E—

P/B—

P/S—

P/FCF—

EPS—

Div yield—

ROE—

ROA—

Debt/Eq—

Current—

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth—

Price target—

Target upside—

Analyst rating—

Institutional0.00%

Ent. value804.83M

Revenue—

Net income0

Gross profit—

Free cash flow—

IndustryBiotechnology

ExchangeNasdaq

Shares out—

Employees—

Listed—

Free float52.95M

Float %85.7%

Short interest81.46K

Days to cover0.4d

Short volume85.5%

Squeeze score22 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction0 / 100

Pattern quality—

Tech rank19.4 / 100

Group rank14 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance30.67

Support13.37

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in OBX

All disclosures →

No recent disclosed trades by Congress in OBX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in OBX

Insider	Side	Shares	Value	Traded	Filed
Barrett Peter Director · Stock Option (Right to Buy) · 2026-08-03	Grant	37.65K	—	2026-08-03	2026-08-05
Fardis Maria Director · Stock Option (Right to Buy) · 2026-08-03	Grant	37.65K	—	2026-08-03	2026-08-05
Hagen Heidi Director · Stock Option (Right to Buy) · 2026-08-03	Grant	37.65K	—	2026-08-03	2026-08-05
Jagasia Madan Chief Executive Officer · Stock Option (Right to Buy) · 2026-08-03	Grant	37.65K	—	2026-08-03	2026-08-05

SEC filings

EDGAR filings in OBX · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.